整合分子测序辅助临床疑似非小细胞肺癌的病理诊断
该研究回顾性分析了1007例因临床怀疑非小细胞肺癌而送检癌症panel二代测序的连续病例,结合临床病史与解剖病理发现,最终12例(1.2%)诊断为肺外来源肿瘤,分子证据包括紫外线相关突变特征(n=6)、基因融合(n=2)和突变(n=4),涉及黑色素瘤、皮肤鳞癌、基底细胞癌、甲状腺癌、尿路上皮癌、肝细胞癌、胰腺腺癌、肝内胆管癌及滑膜肉瘤。
要点
- 临床疑似非小细胞肺癌中,约1.2%经分子测序整合诊断确认为肺外来源肿瘤。
- 分子证据包括紫外线相关突变特征、基因融合和特定突变,可提示非肺原发。
- 整合临床、显微镜和分子证据有助于诊断并指导个体化肿瘤治疗。
核心结论
- 小但不可忽略比例(12/1007,1.2%)的临床疑似非小细胞肺癌经临床二代测序后最终诊断为肺外来源肿瘤。
- 整合临床、显微镜和分子证据可辅助诊断并指导个体化肿瘤治疗。
研究设计与样本
- 回顾性分析1007例连续患者因临床怀疑非小细胞肺癌而送检的癌症panel二代测序结果,并结合临床病史与解剖病理发现。
主要发现
- 12例(1.2%)最终整合诊断为肺外来源肿瘤,支持诊断的分子证据包括紫外线辐射相关突变特征(n=6)、基因融合(n=2)和突变(n=4)。
- 整合诊断包括未分化黑色素瘤、皮肤鳞状细胞癌、基底细胞癌、甲状腺癌、尿路上皮癌、肝细胞癌、胰腺腺癌、肝内胆管癌和滑膜肉瘤。
关键数值与推荐
- 12/1007例(1.2%)最终诊断为肺外来源肿瘤。
- 分子证据:紫外线辐射相关突变特征(n=6)、基因融合(n=2)、突变(n=4)。
临床怎么用
- 对临床疑似非小细胞肺癌的患者,应结合临床、显微镜和分子证据进行整合诊断,分子测序结果可能提示肺外原发肿瘤并指导个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer panel sequencing has been rapidly adopted into clinical practice for the detection of actionable genetic variants in advanced non-small cell lung carcinomas. Unexpected molecular results may lead to reexamination of the clinical diagnosis; however, this scenario has not been systematically evaluated. We reviewed cancer panel next-generation sequencing results from 1007 consecutive patients performed for the clinical indication of non-small cell lung carcinoma along with the corresponding clinical history and anatomical pathology findings. The final integrative diagnosis was a cancer of extrapulmonary origin in 12 of 1007 patients (1.2%). Molecular evidence supporting the final diagnoses included the detection of an UV radiation-associated mutational signature (n = 6), gene fusions (n = 2), and mutations (n = 4). The integrative diagnoses included undifferentiated melanoma, cutaneous squamous cell, and basal cell carcinomas, thyroid carcinoma, urothelial carcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, intrahepatic cholangiocarcinoma, and synovial sarcoma. A small but nonnegligible proportion of clinically suspected non-small cell lung carcinomas had a final diagnosis of cancer of extrapulmonary origin after clinical next-generation sequencing. The integration of clinical, microscopic, and molecular evidence can aid diagnosis and guide personalized oncology care.
引用
- Lo YC, Bauer AH, Odintsov I, et al. Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas. Mod Pathol. 2023. PMID: 36842187. doi:10.1016/j.modpat.2023.100126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。